Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-03-14
DOI
10.3389/fphar.2017.00063
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies
- (2016) Kasper Adelborg et al. HEART
- Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation
- (2016) San-Shuai Chang et al. STROKE
- Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack
- (2015) Priyesh A. Patel et al.
- Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack
- (2015) Priyesh A. Patel et al. Circulation-Cardiovascular Quality and Outcomes
- Adherence to oral anticoagulants in patients with atrial fibrillation—a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol
- (2015) G Sanfélix-Gimeno et al. BMJ Open
- Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications
- (2014) Nihar R. Desai et al. AMERICAN JOURNAL OF MEDICINE
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
- (2014) Craig T. January et al. CIRCULATION
- Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013
- (2014) J. B. Olesen et al. EUROPACE
- Increased risk of myocardial infarction with dabigatran
- (2014) Ada F. Giglio et al. Journal of Cardiovascular Medicine
- Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
- (2014) Jonathan Douxfils et al. Journal of the American Heart Association
- Guided Antithrombotic Therapy: Current Status and Future Research Direction
- (2012) Valentin Fuster et al. CIRCULATION
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
- (2012) et al. EUROPEAN HEART JOURNAL
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
- (2010) Ron Pisters et al. CHEST
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
- (2010) et al. EUROPACE
- 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)
- (2010) L. Samuel Wann et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
- (2009) Gregory Y.H. Lip et al. CHEST
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started